A leading cancer center estimates that “currently only 10% to 20% of patients with actionable mutations actually end up on a [targeted] drug or in a trial.”* How can this be? And what can we do about it?
It’s unfortunate but true—in the reality of clinical cancer care, actionable genomic data by itself does not necessarily translate into saving lives. Inefficient workflows, unstructured data, and lack of software interoperability all stand between a tumor profile result and delivery of a potentially lifesaving drug to a patient. In other words, actionable information is useful only if a physician can act on it.
But Intermountain Healthcare, a Syapse customer, raised the targeted therapy procurement rate to 82% of cancer patients with an actionable somatic mutation by including clinical and molecular data in an integrated workflow that extends to drug procurement and navigation services through their in-house specialty pharmacy. That’s why we built Syapse Oncology—to equip healthcare provider systems with software to implement scalable, efficient precision oncology programs that enable clinicians to act on insights based on patients’ molecular profiles.
With the arrival of two new features—drug ordering and clinical trial enrollment—Syapse Oncology now enables clinicians to go seamlessly from viewing tumor profiling results and clinical decision support to procuring suggested therapies and enrolling patients into molecularly matched clinical trials.
Drug ordering. While “precision medicine” relies on next-generation sequencing technology for precision, this feature is what gets medicine to patients. To determine eligibility for a targeted cancer therapy and route the prescription appropriately—processes that often complicate or block drug procurement entirely—specialty pharmacies need more information than what is included in a prescription (e.g., prior failed therapies, genomic data, lab results). Syapse is replacing what is today a manual process that relies on clinical staff to search for clinical data across multiple systems and copy them to paper forms that are then faxed.
When a clinician clicks the order button in Syapse Oncology, Syapse can electronically send all information necessary to complete any drug procurement forms to the provider’s in-house or preferred specialty pharmacy, eliminating bottlenecks and speeding the delivery of potentially lifesaving drugs to patients.
Clinical trial enrollment forms. This feature systematizes trial eligibility assessment and enrollment across the entire organization. With discrete study eligibility criteria entered into Syapse Oncology as structured data, combined with Syapse’s ability to integrate with EHR and other systems, Syapse Oncology automatically prefills electronic eligibility assessment forms containing trial eligibility criteria with the corresponding patient clinical and molecular data. This feature greatly accelerates trial eligibility assessment and ultimately increases recruitment rates.
With these features, Syapse Oncology plays a major role in our mission to make precision medicine a routine part of the entire cancer care journey, starting with an integrated view of a patient’s clinical history, and extending beyond test orders and results to include drug procurement and enrollment into molecularly matched clinical trials.
* http://on.wsj.com/1ywNCfw (behind paywall)